Sign In
Buy VAXX
$0.0001
+0 (+0%)
At Close: Jun 03, 2026
Vaxxinity to Present at the 2024 J.P. Morgan Healthcare Conference
08:00am, Wednesday, 03'rd Jan 2024
CAPE CANAVERAL, Fla., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced that Mei Mei Hu, Chief Ex
Alzheimer's Disease Space Evolves in 2023: Stocks in Focus
10:32am, Monday, 11'th Dec 2023
The approval of the breakthrough treatment Leqembi for Alzheimer's Disease has put this space in the spotlight. Companies like ACIU, VAXX and PRTA are in focus, given their experimental vaccines.
Vaxxinity to Present at Upcoming November Medical and Investor Conferences
06:50pm, Monday, 13'th Nov 2023
CAPE CANAVERAL, Fla., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced that its scientists and e
Vaxxinity Reports Third Quarter 2023 Financial Results and Provides Corporate Update
08:30am, Wednesday, 08'th Nov 2023
CAPE CANAVERAL, Fla., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today reported financial results for the
Down -22.18% in 4 Weeks, Here's Why You Should You Buy the Dip in Vaxxinity, Inc. (VAXX)
11:17am, Thursday, 07'th Sep 2023
The heavy selling pressure might have exhausted for Vaxxinity, Inc. (VAXX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street ana
Vaxxinity to Present at Upcoming Investor Conferences in September
08:00am, Tuesday, 29'th Aug 2023
CAPE CANAVERAL, Fla., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced that Mei Mei Hu, Chief Ex
Phase 2a data published in The Lancet's eBioMedicine supports further development of UB-311 The paper concludes that UB-311 is the most advanced active immunotherapy targeting beta-amyloid in the clin
Vaxxinity Reports Second Quarter 2023 Financial Results and Provides Corporate Update
08:00am, Wednesday, 09'th Aug 2023
CAPE CANAVERAL, Fla., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today reported financial results for the
Vaxxinity Appoints Peter Powchik, M.D., to Executive Vice President, Global Scientific Director
04:30pm, Thursday, 27'th Jul 2023
Appointment adds Dr. Powchik's experience in the development of marketed immunotherapeutics to Vaxxinity's leadership team
Vaxxinity to Present at World Vaccine Congress, American Academy of Neurology, and BNA2023 Festival of Neuroscience in April
08:00am, Tuesday, 28'th Mar 2023
Vaxxinity CEO Mei Mei Hu to participate in fireside chat with Sarah Despres, Counselor to the Secretary for Public Health and Science, U.S. Department of Health and Human Services, at World Vaccine Co
Vaxxinity to Present at Upcoming March Scientific and Medical Conferences
08:00am, Thursday, 02'nd Mar 2023
Vaxxinity to present new preclinical data on anti-tau Alzheimer's vaccine candidate VXX-301 at AD/PD International Conference Vaxxinity to present new preclinical data on anti-tau Alzheimer's vaccine
The 5 Best and Worst Performing Small-Cap Stocks in January 2023
10:51pm, Monday, 13'th Feb 2023
Small-cap stocks are expected to perform well this year. The Bank of America Securities, in fact, is asking investors to consider small caps this year to hedge against a declining market.
Why Shares of Vaxxinity Jumped This Week
02:04pm, Thursday, 19'th Jan 2023
Investors are hoping the company's COVID-19 vaccine will turn the company from a clinical-stage biotech to a commercial one.
Vaxxinity: Potential Strong Upsides Ahead
07:58am, Tuesday, 17'th Jan 2023
We may not be at the end credits for COVID-19 virus. Shares of Vaxxinity, Inc., like most biotechs, have plummeted over the past year due to unprecedented market headwinds, both macroeconomic and geop
Why Shares of Vaxxinity Soared This Week
05:30am, Friday, 02'nd Dec 2022
Positive news regarding a different company's Alzheimer's treatment may have helped Vaxxinity.
